Skip to main content Back to Top
Advertisement

4/18/2024

Cromolyn Oral Solution

Products Affected - Description

    • Cromolyn sodium oral solution, Micro Labs, 100 mg/5 mL, 5 mL ampule, 96 count, NDC 42571-0132-52
    • Cromolyn sodium oral solution, Rising Pharmaceuticals, 100 mg/5 mL, 5 mL ampule, 96 count, NDC 16571-0600-96
    • Cromolyn sodium oral solution, Ritedose, 100 mg/5 mL, 5 mL ampule, 96 count, NDC 76204-0025-96
    • Cromolyn sodium oral solution, Wallace Pharmaceuticals, 100 mg/5 mL, 5 mL ampule, 96 count, NDC 51525-0470-09 - discontinued
    • Cromolyn sodium oral solution, Woodward, 100 mg/5 mL, 5 mL ampule, 96 count, NDC 69784-0200-96

Reason for the Shortage

    • Micro Labs did not provide a reason for the shortage.
    • Mylan (Viatris) / Wallace has Gastrocrom oral solution available.
    • Rising did not provide a reason for the shortage.
    • Ritedose recalled one lot of cromolyn oral solution in July 2023 due to manufacturing issues.
    • Woodward did not provide a reason for the shortage.

Available Products

    • Gastrocrom oral solution, Mylan (Viatris), 100 mg/5 mL, 5 mL ampule, 96 count, NDC 00037-0678-96

Estimated Resupply Dates

    • Micro Labs has cromolyn 100 mg/5 mL oral solution on allocation.
    • Rising has cromolyn 100 mg/5 mL oral solution on intermittent back order and the company is releasing supplies as they become available.
    • Ritedose has cromolyn 100 mg/5 mL oral solution in limited supply.
    • Woodward has cromolyn 100 mg/5 mL oral solution on allocation.

Updated

Updated April 18, 2024 by Leslie Jensen, PharmD, Drug Information Specialist. Created October 19, 2023 by Leslie Jensen, PharmD, Drug Information Specialist. © 2024, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.

ADVERTISEMENT